Physician profile
Serdar E Bulun
NPI 1750340113
$9,535.00
in general payments reported to CMS, 2019-2025
3 companies · $3,065 in 2025
The $3,065 reported for 2025 was more than what 94% of Reproductive Endocrinology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,675 · 2023: $3,795 · 2025: $3,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,860.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $3,795.00 | 2023 | |
| Regeneron Pharmaceuticals, INC. | $3,065.00 | 2025 | |
| Myovant Sciences INC. | $2,675.00 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Serdar Bulun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.